Clinical Epigenetics · 2021 · 26 citations · 70 references
MedicineBioinformaticsOncologyEpigenomicsGynecologic OncologyMolecular OncologyCancer BiomarkersCancer EpigeneticsDna Methylation ProfilingEpigenetic Alterations In CancerEpigenetic Biomarker AnalysisOvarian CancerCancer Dna Methylation SignaturesCancer Epigenetic BiomarkersDifferential Methylation AnalysisGenome-wide Methylation AssaysHigh-grade Serous Ovarian CarcinomaKaplan-meier Survival EstimatesMethylation ArraysSerous Ovarian Tumors
BACKGROUND: Primary or acquired chemoresistance is a key link in the high mortality rate of ovarian cancer. There is no reliable method to predict chemoresistance in ovarian cancer. We hypothesized that specific methylation characteristics could distinguish chemoresistant and chemosensitive ovarian cancer patients. METHODS: In this study, we used 450 K Infinium Methylation BeadChip to detect the different methylation CpGs between ovarian cancer patients. The differential methylation genes were analyzed by GO and KEGG Pathway bioinformatics analysis. The candidate CpGs were confirmed by pyrosequencing. The expression of abnormal methylation gene was identified by QRT-PCR and IHC. ROC analysis confirmed the ability to predict chemotherapy outcomes. Prognosis was evaluated using Kaplan-Meier. RESULTS: In advanced high-grade serous ovarian cancer, 8 CpGs (ITGB6:cg21105318, cg07896068, cg18437633; NCALD: cg27637873, cg26782361, cg16265707; LAMA3: cg20937934, cg13270625) remained hypermethylated in chemoresistant patients. The sensitivity, specificity and AUC of 8 CpGs (ITGB6:cg21105318, cg07896068, cg18437633; NCALD: cg27637873, cg26782361, cg16265707; LAMA3: cg20937934, cg13270625) methylation to predict chemotherapy sensitivity were 63.60-97.00%, 46.40-89.30% and 0.774-0.846. PFS of 6 candidate genes (ITGB6:cg21105318, cg07896068; NCALD: cg27637873, cg26782361, cg16265707; LAMA3: cg20937934) hypermethylation patients was significantly shorter. The expression of NCALD and LAMA3 in chemoresistant patients was lower than that of chemosensitive patients. Spearman analysis showed that NCALD and LAMA3 methylations were negatively correlated with their expression. CONCLUSIONS: As a new biomarker of chemotherapy sensitivity, hypermethylation of NCALD and LAMA3 is associated with poor PFS in advanced high-grade serous ovarian cancer. In the future, further research on NCALD and LAMA3 will be needed to provide guidance for clinical stratification of demethylation therapy.
70
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Ovarian cancer statistics, 2018
Lindsey A. Torre, Britton Trabert, Carol DeSantis et al. · CA A Cancer Journal for Clinicians · 2018 · 3.7K citations · Full text
Medicine, Gynecology, Oncology +16
Éric Pujade-Lauraine, Jonathan A. Ledermann, Frédèric Selle et al. · The Lancet Oncology · 2017 · 1.9K citations
Pharmacy, Oncology, Pharmacotherapy +14
Whole–genome characterization of chemoresistant ovarian cancer
Ann‐Marie Patch, Elizabeth L. Christie, Dariush Etemadmoghadam et al. · Nature · 2015 · 1.6K citations
Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumors
Toshiyasu Taniguchi, Marc Tischkowitz, Najim Ameziane et al. · Nature Medicine · 2003 · 543 citations · Full text